Skip to Content

Boston-based drugmaker Vertex, which specializes in rare disorders like cystic fibrosis, doesn’t always attract Big Pharma–level attention. But the firm is on a serious growth trajectory, slated for double-digit expansion in the coming years, per analysts. And the company is branching out into new, brand-name science it hopes can add to its $43 billion market value, including a recent $950 million deal to acquire Semma Therapeutics—a startup that aims to use stem cells to cure Type 1 diabetes.

Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

Company Information

Overall Score2.6
Sector
Health Care
Industry
Biotechnology
CEO
Jeffrey Leiden
Websitehttps://www.vrtx.com
HQ Location
Boston
Country
U.S.
Revenues ($M) (Past 12 Months)$3,454
Profits ($M) (Past 12 Months)$2,215
Market Value as of Oct. 9, 2019 ($M)$43,370
Employees2,500

Refinitiv Sustainable Leadership Monitor

placeholder